1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

15 Dec 2022
Admin
News Article

Takeda Launches Cinryze In India For Prophylaxis In Hereditary Angioedema Patients

Biopharmaceutical Major Takeda Biopharmaceuticals India Private Limited (Formerly Known As Baxalta Bioscience India Pvt. Ltd.) Has Launched Cinryze, An Innovative Injectable Prescription Medicine For The Treatment Of Hereditary Angioedema (Hae) Patients.With Eight Years Of Global Clinical Experience Proving Efficacy And Safety, Cinryze Has The Potential To Mark A Breakthrough In The Episodic Treatment, Short And Long-Term Prophylaxis For Hae.Moreover, Cinryze Is The Pioneer C1 Esterase Inhibitor (C1-I Nh) Approved By The Us Food And Drug Administration (Fda) And European Medicines Agency (Ema) For The Symptomatic Management Of Hae And For Preventing Future Angioedema Attacks.Cinryze Is Indicated In India For Routine Prevention (Prophylaxis) Of Angioedema Attacks In Adults, Adolescents And Children 6 Years Of Age And Above With Hae, Treatment Of Angioedema Attacks And Pre-Procedure Prevention Of Angioedema Attacks In Adults, Adolescents And Children 2 Years Of Age And Above With Hae.The Disease Is Usually Identified By Recurrent Episodes Of Fluid Accumulation Outside The Blood Vessels, Causing Rapid Swelling Of Body Tissues. The Symptoms Of Hae Could Be Like An Allergic Reaction; However, The Potential Outcome Could Be Life-Threatening In Case Of Hae. Due To The Lack Of Awareness Among Healthcare Professionals, Hae Is Highly Underdiagnosed In The Country.Speaking At The Launch, Serina Fischer, General Manager, Takeda Biopharmaceuticals India Private Limited Said,

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!